Who wouldn't love a stock that has more than doubled in a little over five months? That's exactly what Dynavax Technologies (NASDAQ: DVAX) has done, thanks partially to good news in April for its COVID-19 vaccine partner Valneva.
Dynavax announced its first-quarter results after the market closed on Thursday. Its momentum seems likely to continue, with the biotech stock rising nearly 6% in after-hours trading. Here are the highlights from Dynavax's Q1 update.
Image source: Getty Images.
For further details see:
How Dynavax Demolished Expectations With Its Q1 Results